Bart Jessen
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Physiology top 5%
Papers in
-
- Retinoids in leukemia and cellular processes 3
- Oncology 13
- Cancer-related Molecular Pathways 8
- Cancer Immunotherapy and Biomarkers 3
- Co-authors
- Shuyan Lu (9 shared papers)Yvonne Will (3 shared papers)Sashi Nadanaciva (2 shared papers)Tae Sung (5 shared papers)Wenyue Hu (8 shared papers)David F. Gebhard (1 shared paper)William D. Pennie (1 shared paper)Robert H. Rice (5 shared papers)
- Journals
- Toxicological Sciences (5 papers)Journal of Ocular Pharmacology and Therapeutics (3 papers)Molecular Cancer Therapeutics (3 papers)Toxicology in Vitro (3 papers)Toxicologic Pathology (3 papers)
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Bart Jessen
45 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 100
- Oncology 476
- Physiology 79
- Immunology 222
- Cell Biology 136
- Ophthalmology 73
Countries citing papers authored by Bart Jessen
This map shows the geographic impact of Bart Jessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Jessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Jessen more than expected).
Fields of papers citing papers by Bart Jessen
This network shows the impact of papers produced by Bart Jessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Jessen. The network helps show where Bart Jessen may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart Jessen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 207 | |
| 2 | 2008 | 171 | |
| 3 | 2010 | 158 | |
| 4 | 2015 | 132 | |
| 5 | 2017 | 109 | |
| 6 | 2002 | 64 | |
| 7 | 2013 | 48 | |
| 8 | 2007 | 37 | |
| 9 | 2003 | 34 | |
| 10 | 2012 | 33 | |
| 11 | 2009 | 32 | |
| 12 | 1995 | 31 | |
| 13 | 2001 | 27 | |
| 14 | 2018 | 23 | |
| 15 | 2021 | 22 | |
| 16 | 2012 | 20 | |
| 17 | 2012 | 18 | |
| 18 | 2004 | 18 | |
| 19 | 2006 | 18 | |
| 20 | 2000 | 17 |
About Bart Jessen
Bart Jessen is a scholar working on Molecular Biology, Oncology, Cell Biology, Pulmonary and Respiratory Medicine and Ophthalmology, having authored 46 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (8 papers), Advanced Breast Cancer Therapies (6 papers), Glaucoma and retinal disorders (5 papers), Microtubule and mitosis dynamics (5 papers), Skin and Cellular Biology Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Retinoids in leukemia and cellular processes (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Oncology (476 citations), Physiology (79 citations), Immunology (222 citations), Cell Biology (136 citations) and Ophthalmology (73 citations). Bart Jessen has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Shuyan Lu, Yvonne Will, Sashi Nadanaciva, Tae Sung, Wenyue Hu, David F. Gebhard, William D. Pennie, Robert H. Rice, Brad Hirakawa and Lisa D. Marroquin. Their work appears in journals such as Toxicological Sciences, Journal of Ocular Pharmacology and Therapeutics, Molecular Cancer Therapeutics, Toxicology in Vitro and Toxicologic Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.